-
Nov 29, 2024 | 
harmreductionjournal.biomedcentral.com | Aix Marseille |Aix Marseille Univ
Correction: Implementation of a community-based LC-UV drug checking service: promising preliminary findings on feasibility and validity Correction Open access Published: 29 November 2024 Harm Reduction Journal volume 21, Article number: 213 (2024) Cite this article The Original Article was published on 18 October 2024 Correction: Harm Reduction Journal (2024) 21:185 In the original version of this article [1], the given and family names of author Nicolas Fabresse was inadvertently swapped in...
-
Nov 21, 2024 | 
bmccancer.biomedcentral.com | Daniel S.W |Therapeutic Innovations |Aix Marseille |Faculté de Médecine
Department of Biomedical Sciences, Humanitas University, Milan, Italy Armando Santoro Department of Oncology and Hematology, IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Via Manzoni 56, Rozzano, Milan, 20089, Italy Armando Santoro Department of Medical Oncology, Hospital Ramón Y Cajal, Madrid, Spain Garrido Pilar Department of Medical Oncology, National Cancer Center Singapore, Singapore, Singapore Daniel S.W. Tan Department of Medical Oncology, University Hospital, 12 de...
-
Oct 23, 2024 | 
bmccancer.biomedcentral.com | Daniel S.W |Therapeutic Innovations |Aix Marseille |Faculté de Médecine
On the data cut-off date (July 29, 2021), 112 of 156 patients completed screening and 111 patients were enrolled in the dose-confirmation and dose-expansion parts of the study. One patient was not treated due to physician’s decision. The primary reason for treatment discontinuation was disease progression (Supplementary Figure S2). Baseline demographics and disease characteristics are presented in Table 1. Overall, baseline characteristics across the treatment groups were well balanced.
-
Oct 18, 2024 | 
harmreductionjournal.biomedcentral.com | Aix Marseille |Aix Marseille Univ
Our LC-UV LC-HRMS cross-validation analysis highlighted that LC-UV is a reliable method for DCS in the context of HR programs for PWUD. More specifically, for the main substances used by PWUD (cocaine, ketamine, MDMA, heroin, amphetamine) and for associated cutting agents (caffeine, acetaminophen, and levamisole), there was no significant bias (≤ 20%) between the results obtained with LC-UV and those obtained with a validated LC-HRMS method.
-
Jul 29, 2024 | 
academic.oup.com | Aix Marseille
This scientific commentary refers to ‘The interictal suppression hypothesis is the dominant differentiator of seizure onset zones in focal epilepsy’ by Doss et al. (https://doi.org/10.1093/brain/awae189). For patients with medically refractory focal epilepsies, epilepsy surgery represents the most effective treatment option.
-
Jun 18, 2024 | 
academic.oup.com | Gower Street |Campus UAB |Aix Marseille
Type Ia supernovae (SNe Ia) magnitudes may be standardized using an empirical relationship derived from properties of their light curves and colours (Phillips 1993; Tripp & Branch 1999) and an additional environmental adjustment which accounts for properties of the SN Ia host galaxy (Kelly et al. 2010; Lampeitl et al. 2010; Sullivan et al. 2010). After standardization, the remaining intrinsic scatter (due to variation of the explosions) is approximately mag.
-
May 29, 2024 | 
academic.oup.com | De Maria |Aix Marseille
A 14-month-old female of European descent was referred to our hospital due to inconclusive sweat chloride tests (STs) and a previous positive newborn screening (NBS) for cystic fibrosis (CF). The patient was born at full-term as the firstborn in a family with no history of genetic diseases. On her third day of life, NBS showed high immunoreactive trypsinogen levels (triplicate average: 109 ng/mL) above the reference level (99.5th percentile: 65 ng/mL).
-
Apr 20, 2024 | 
link.springer.com | Cardiovascular Diseases |Metabolic Diseases |Aix Marseille |Gustave Roussy
Correction to: Diabetes Ther (2024) 15:1349–1360 https://doi.org/10.1007/s13300-024-01577-8In the original article, the figure 1 caption was published incorrectly as Adjusted Kaplan–Meier survival curves for the persistence with basal insulin therapy in the newly treated patients (T1DM right curves, T2DM left curves). The correct caption is Adjusted Kaplan–Meier survival curves for the persistence with basal insulin therapy in the newly treated patients (T1DM left curves, T2DM right curves).
-
Apr 19, 2024 | 
link.springer.com | Cardiovascular Diseases |Metabolic Diseases |Aix Marseille |Gustave Roussy
AbstractSecond-generation basal insulins like glargine 300 U/mL (Gla-300) have a longer duration of action and less daily fluctuation and interday variability than first-generation ones, such as glargine 100 U/mL (Gla-100). The EF-BI study, a nationwide observational, retrospective study, was designed to compare persistence, acute care complications, and healthcare costs associated with the initiation of such basal insulins (BI) in a real-life setting in France.
-
Apr 1, 2024 | 
link.springer.com | Aix Marseille |IHU Méditerranée Infection
Retraction of: Scientific Reports https://doi.org/10.1038/s41598-017-17132-4, published online 01 December 2017Editors have retracted this Article. After publication of this paper concerns about ethical oversight of this study were brought to the attention of the Editors. The paper cites approval from an institutional ethics committee in France, but samples used in this study were also sourced from Algeria, Saudi Arabia, and Niger.
